ArticleBritish journal of pharmacology2006
Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation.
Article in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 118 citations in OpenAlex.
- Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.Journal of immunology (Baltimore, Md. : 1950) · 2015Trial
- Misoprostol in Refractory Neuralgic Pain: From Clinical Neurology to an EP-Receptor Hypothesis of Pharmacodynamic Persistence.International journal of molecular sciences · 2026Review
- Identifying key molecular interactions and pathways linking DEHP and its metabolite MEHP to allergic rhinitis: a network toxicology and molecular dynamics study.BMC pharmacology & toxicology · 2026Article
- Mast cell-specific CysLT2 receptor signaling inhibits cysteinyl leukotriene-dependent mast cell activation and type 2 allergic lung inflammation.Cell reports · 2026Article
- Acetylsalicylic acid aggravates anaphylaxis in a PGE2-dependent manner.The Journal of clinical investigation · 2025Article
- New insights into the mechanisms of aspirin-exacerbated respiratory disease.Current opinion in allergy and clinical immunology · 2025Review
- Bone: A Neglected Endocrine Organ?Journal of clinical medicine · 2024Review
- Article
- [Altered expression of 15-hydroxyprostaglandin dehydrogenase in chronic rhinosinusitis with nasal polyps].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023Article
- Recent Updates in Understanding NSAID Hypersensitivity.Current allergy and asthma reports · 2023Review
- Updates on immune mechanisms in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2023Review
- Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions.European journal of immunology · 2021Review
- Angioedema and Fatty Acids.International journal of molecular sciences · 2021Review
- Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021Review
- Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment.NPJ genomic medicine · 2021Article
- Article
- Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis.Allergy · 2020Article
- The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.International journal of molecular sciences · 2020Review
- The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics.Journal of asthma and allergy · 2020Review
- Mesenchymal Stem Cells and Atopic Dermatitis: A Review.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prostanoid, PGE2, is known to inhibit human lung mast cell activity. The aim of the present study was to characterize the EP receptor that mediates this effect. PGE2 (pEC(50), 5.8+/-0.1) inhibited the IgE-mediated release of histamine from mast cells in a concentration-dependent manner. Alternative EP receptor agonists were studied. The EP2-selective agonist, butaprost (pEC50, 5.2+/-0.2), was an effective inhibitor of mediator release whereas the EP1/EP3 receptor agonist, sulprostone, and the EP1-selective agonist, 17-phenyl-trinor-PGE2, were ineffective. The DP agonist PGD2, the FP agonist PGF(2alpha), the IP agonist iloprost and the TP agonist U-46619 were ineffective inhibitors of IgE-mediated histamine release from mast cells. PGE2 induced a concentration-dependent increase in intracellular cAMP levels in mast cells. The effects of the EP1/EP2 receptor antagonist, AH6809, and the EP4 receptor antagonist, AH23848, on the PGE2-mediated inhibition of histamine release were determined. AH6809 (pK(B), 5.6+/-0.1) caused a modest rightward shift in the PGE2 concentration-response curve, whereas AH23848 was ineffective. Long-term (24 h) incubation of mast cells with either PGE2 or butaprost (EP2 agonist), but not sulprostone (EP1/EP3 agonist), caused a significant reduction in the subsequent ability of PGE2 to inhibit histamine release. Collectively, these data suggest that PGE2 mediates effects on human lung mast cells by interacting with EP2 receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.